Abstract
Many facets of drug discovery involve the use of patented materials and methods, subjecting the researcher to potential liability from infringement of the underlying patents. Enacted in 1984, the Hatch-Waxman Act established a “safe harbor” for activities that would otherwise constitute infringement of a patented invention, if those activities were “solely for uses reasonably related to the development and submission of information under a Federal law which regulates the manufacture, use, or sale of drugs or veterinary biological products”. This article examines the major court decisions interpreting the scope of the safe harbor and their application to various activities in drug development.
Keywords: Research tools, Merck, AbTox, Eli Lilly, Proveris, Safe Harbor Provision, Hatch-Waxman Act, Federal law, Investigational New Drug Applica-tion, New Drug Ap-plication, Patent Term Restoration Act, Abbreviated New Drug, flurazepam, Federal Food, Drug, and Cosmetic Act, hybridoma tech-nology, FDCA, PHS Act, Federal Circui, FDA regulation, Arg-Gly-Asp, RGD, Merck's preclinical experimentation, ANDA, EMD 121974, v3 receptors, angio-matrigel test, FDA's guidelines, U.S. Patent No. 4,879,237, U.S. Patent No. 4,789,734, IC50 or EC50
Current Topics in Medicinal Chemistry
Title: Drug Discovery and the Impact of the Safe Harbor Provision of the Hatch-Waxman Act
Volume: 10 Issue: 18
Author(s): Susanne H. Goodson
Affiliation:
Keywords: Research tools, Merck, AbTox, Eli Lilly, Proveris, Safe Harbor Provision, Hatch-Waxman Act, Federal law, Investigational New Drug Applica-tion, New Drug Ap-plication, Patent Term Restoration Act, Abbreviated New Drug, flurazepam, Federal Food, Drug, and Cosmetic Act, hybridoma tech-nology, FDCA, PHS Act, Federal Circui, FDA regulation, Arg-Gly-Asp, RGD, Merck's preclinical experimentation, ANDA, EMD 121974, v3 receptors, angio-matrigel test, FDA's guidelines, U.S. Patent No. 4,879,237, U.S. Patent No. 4,789,734, IC50 or EC50
Abstract: Many facets of drug discovery involve the use of patented materials and methods, subjecting the researcher to potential liability from infringement of the underlying patents. Enacted in 1984, the Hatch-Waxman Act established a “safe harbor” for activities that would otherwise constitute infringement of a patented invention, if those activities were “solely for uses reasonably related to the development and submission of information under a Federal law which regulates the manufacture, use, or sale of drugs or veterinary biological products”. This article examines the major court decisions interpreting the scope of the safe harbor and their application to various activities in drug development.
Export Options
About this article
Cite this article as:
H. Goodson Susanne, Drug Discovery and the Impact of the Safe Harbor Provision of the Hatch-Waxman Act, Current Topics in Medicinal Chemistry 2010; 10 (18) . https://dx.doi.org/10.2174/156802610793176693
DOI https://dx.doi.org/10.2174/156802610793176693 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Microbiota and Probiotics in Stress-Induced Gastrointestinal Damage
Current Molecular Medicine Electrotransfer into Skeletal Muscle for Protein Expression
Current Gene Therapy Protein Kinase B/AKT and Focal Adhesion Kinase: Two Close Signaling Partners in Cancer
Anti-Cancer Agents in Medicinal Chemistry Antidepressants: Update on Benefits and Risks
Current Psychopharmacology Endothelial Progenitors in Vascular Repair and Angiogenesis: How Many are Needed and What to do?
Cardiovascular & Hematological Disorders-Drug Targets Novel Anticancer Targets and Drug Discovery in Post Genomic Age
Current Medicinal Chemistry - Anti-Cancer Agents The Effects of Curcumin on Immune Responses
Current Bioactive Compounds Identification of WDFY3 Neoantigens as Prognostic Markers in Longterm Survivors of Extrahepatic Cholangiocarcinoma
Current Cancer Drug Targets New Approaches to the Modulation of the Cyclooxygenase-2 and 5-Lipoxygenase Pathways
Current Topics in Medicinal Chemistry Plasma-Free Amino Acid Profiling of Nasal Polyposis Patients
Combinatorial Chemistry & High Throughput Screening Differential Enhancement of T Helper Type 1 (Th1)/Th2 Cytokine Production by Natural Killer T Cells Through Negative Feedback Regulation with Cytokine-conditioned Dendritic Cells
Current Immunology Reviews (Discontinued) Signal Transducer and Activator of Transcription 3 Signaling Pathway: A Potential Target in Sarcoma Treatment
Current Enzyme Inhibition Electro-Acupuncture Protects Diabetic Nephropathy-Induced Inflammation Through Suppression of NLRP3 Inflammasome in Renal Macrophage Isolation
Endocrine, Metabolic & Immune Disorders - Drug Targets Updates of mTOR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets A Review on Chemical Profile of Coumarins and their Therapeutic Role in the Treatment of Cancer
Current Drug Delivery AP5346 (ProLindac™), A DACH Platinum Polymer Conjugate in Phase II Trials Against Ovarian Cancer
Current Bioactive Compounds Analysis of DNA Microarray Data
Current Topics in Medicinal Chemistry Autophagy after Subarachnoid Hemorrhage: Can Cell Death be Good?
Current Neuropharmacology The Critical Roles of HSC70 in Physiological and Pathological Processes
Current Pharmaceutical Design